Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found no meaningful improvement in the overall survival for EPKINLY (epcoritamab) monotherapy when compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) ...

BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy and boosted its price target from $115 to $142, highlighting the company’s key position in oncology. According to the firm, BioNTech SE (NASDAQ:BNTX) stands “at the nexus of significant developments occurring in the oncology field,” particularly in next-generation immuno-oncology and antibody-drug conjugates (ADCs). Zoetis (ZTS) Hits New 52- ...

Argenx SE (NASDAQ:ARGX) ranks among the best high growth European stocks to buy. On January 12, William Blair maintained its Outperform rating on Argenx SE (NASDAQ:ARGX), citing robust sales growth in the company’s Vyvgart brand. The firm reports that Vyvgart sales stay ahead of expectations and demonstrate solid momentum, which it expects to last through 2026 across authorized applications in MG (myasthenia gravis) and CIDP. The firm also emphasized the potential of Argenx’s other clinical products, inc ...

Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential. On January 7, UBS assumed coverage of Arcellx with a Buy rating and $100 price target as the firm assumed coverage on 22 small-to-mid cap biotech names. Contending that biotech fundamentals are now inflecting after a rough period, UBS expects investor confidence to recover and sees this positioning the sector for strong performance in 2026. Earlier on December 22, Wells Fargo initiated coverage of Arcel ...

Morgan Stanley has set a new price target for NASDAQ:GUTS at $2, indicating a potential increase of about 245% from its current trading price.The stock has experienced a significant decrease of 68.04%, trading at $0.58, down from its previous levels.GUTS has shown volatility with a yearly high of $3.03 and a low of $0.56, alongside a trading volume of 87.51 million shares, reflecting active investor interest.GUTS, trading on the NASDAQ, is currently under the spotlight following Morgan Stanley's price targe ...

FDA Submission Marks a Pivotal Milestone in Advancing Early Cancer Detection, Addressing Unmet Needs in Cancer Screening ® MENLO PARK, Calif., Jan. 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri multi-cancer early detection (MCED) test. The FDA designated the test ...

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Regenxbio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 28, 2026, ...

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Vistagen and certain of ...

As filed with the Securities and Exchange Commission on January 29, 2026 Registration No. 333-291852 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Edison Oncology Holding Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Nevada 2836 83-1614120 (I.R.S. Employer Identification Number) 3475 Edison Way, S ...

Core Viewpoint - Regenxbio Inc. is under investigation for potential discrepancies between the information provided to investors and the actual safety developments in its gene therapy clinical programs, particularly following the FDA's clinical holds on its RGX-111 and RGX-121 programs due to safety concerns [1][2]. Group 1: Company Developments - On January 28, 2026, Regenxbio disclosed that the FDA placed clinical holds on its RGX-111 and RGX-121 programs after a tumor was identified in a trial participant, leading to a 30-35% decline in the company's share price [2]. - During the Q3 2025 earnings call on November 6, 2025, CEO Curran Simpson highlighted positive regulatory interactions, noting that the FDA completed inspections of clinical sites and the manufacturing facility with no observations, which may have created an asymmetric presentation of the company's regulatory standing [4]. - The Q3 2025 earnings call transcript did not mention the RGX-111 program for MPS I, despite it being a significant pipeline asset that would later face the same FDA clinical hold, raising concerns about the completeness of information provided to shareholders [5]. Group 2: Regulatory and Legal Context - SEC disclosure rules require public companies to provide material information necessary for informed investment decisions, and Rule 10b-5 prohibits material misstatements and omissions in securities transactions [3].